产品
编 号:F712230
分子量:5667.5
产品类型
规格
价格
是否有货
结构图
联系客服
产品详情
生物活性:
Oblimersen is a BCL-2 inhibitor targeting BCL-2 RNA. Oblimersen specifically binds to the first six codons of the bcl-2 mRNA sequence, resulting in degradation of bcl-2 mRNA and induces apoptosis by down-regulating expression of Bcl-2. Oblimersen can be used for cancer research.

体内研究:
Oblimersen (10 mg/kg; i.p.; daily, for 6 days; nude mice bearing H69 xenografts) decreases tumoural vascularisation in vivo.Oblimersen (5-10 mg/kg; i.p.; daily (Monday to Friday), for 3 weeks) has antitumor efficacy in the subcutaneous tumor model.Animal Model:Male severe combined immunodeficient (SCID)-RAG2 mice
Dosage:5 and 10 mg/kg
Administration:Intraperitoneal injection; daily (Monday to Friday), for 3 weeks
Result:Inhibited tumor growth in a dose-dependent manner.

体外研究:
Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) decreases BCL-2 protein expression in vitro.Oblimersen (500 nM; 72 hours; human small-cell lung cancer cell lines H69) increases radiation-induced apoptosis.
产品资料